Histotype  ||| S:0 E:10 ||| JJ
differentiation  ||| S:10 E:26 ||| NN
of  ||| S:26 E:29 ||| IN
hypo-echoic  ||| S:29 E:41 ||| JJ
renal  ||| S:41 E:47 ||| JJ
tumors  ||| S:47 E:54 ||| NNS
on  ||| S:54 E:57 ||| IN
CEUS ||| S:57 E:61 ||| NNP
:  ||| S:61 E:63 ||| :
usefulness  ||| S:63 E:74 ||| NN
of  ||| S:74 E:77 ||| IN
enhancement  ||| S:77 E:89 ||| JJ
homogeneity  ||| S:89 E:101 ||| NN
and  ||| S:101 E:105 ||| CC
intensity  ||| S:105 E:115 ||| NN
The  ||| S:115 E:119 ||| DT
purpose  ||| S:119 E:127 ||| NN
of  ||| S:127 E:130 ||| IN
this  ||| S:130 E:135 ||| DT
study  ||| S:135 E:141 ||| NN
is  ||| S:141 E:144 ||| VBZ
to  ||| S:144 E:147 ||| TO
evaluate  ||| S:147 E:156 ||| VB
qualitative  ||| S:156 E:168 ||| NNS
and  ||| S:168 E:172 ||| CC
quantitative  ||| S:172 E:185 ||| JJ
analysis  ||| S:185 E:194 ||| NN
of  ||| S:194 E:197 ||| IN
contrast-enhanced  ||| S:197 E:215 ||| JJ
ultrasound  ||| S:215 E:226 ||| NN
( ||| S:226 E:227 ||| -LRB-
CEUS ||| S:227 E:231 ||| NNP
)  ||| S:231 E:233 ||| -RRB-
in  ||| S:233 E:236 ||| IN
differential  ||| S:236 E:249 ||| JJ
diagnoses  ||| S:249 E:259 ||| NN
of  ||| S:259 E:262 ||| IN
hypo-echoic  ||| S:262 E:274 ||| JJ
renal  ||| S:274 E:280 ||| JJ
tumor  ||| S:280 E:286 ||| NN
histotypes ||| S:286 E:296 ||| NN
.  ||| S:296 E:298 ||| .
Our  ||| S:298 E:302 ||| PRP$
study  ||| S:302 E:308 ||| NN
cohort  ||| S:308 E:315 ||| VBZ
comprised  ||| S:315 E:325 ||| VBN
103  ||| S:325 E:329 ||| CD
clear  ||| S:329 E:335 ||| JJ
cell  ||| S:335 E:340 ||| NN
renal  ||| S:340 E:346 ||| JJ
cell  ||| S:346 E:351 ||| NN
carcinomas  ||| S:351 E:362 ||| NNS
( ||| S:362 E:363 ||| -LRB-
ccRCCs ||| S:363 E:369 ||| NNP
) ||| S:369 E:370 ||| -RRB-
,  ||| S:370 E:372 ||| ,
24  ||| S:372 E:375 ||| CD
papillary  ||| S:375 E:385 ||| CD
renal  ||| S:385 E:391 ||| JJ
cell  ||| S:391 E:396 ||| NN
carcinomas  ||| S:396 E:407 ||| NNS
( ||| S:407 E:408 ||| -LRB-
pRCCs ||| S:408 E:413 ||| NNP
) ||| S:413 E:414 ||| -RRB-
,  ||| S:414 E:416 ||| ,
28  ||| S:416 E:419 ||| CD
chromophobe  ||| S:419 E:431 ||| CD
renal  ||| S:431 E:437 ||| JJ
cell  ||| S:437 E:442 ||| NN
carcinomas  ||| S:442 E:453 ||| NNS
( ||| S:453 E:454 ||| -LRB-
cRCCs ||| S:454 E:459 ||| NNP
) ||| S:459 E:460 ||| -RRB-
,  ||| S:460 E:462 ||| ,
and  ||| S:462 E:466 ||| CC
34  ||| S:466 E:469 ||| CD
angiomyolipomas  ||| S:469 E:485 ||| NNS
( ||| S:485 E:486 ||| -LRB-
AMLs ||| S:486 E:490 ||| NNP
) ||| S:490 E:491 ||| -RRB-
,  ||| S:491 E:493 ||| ,
hypo-echoic  ||| S:493 E:505 ||| JJ
on  ||| S:505 E:508 ||| IN
ultrasound ||| S:508 E:518 ||| NN
,  ||| S:518 E:520 ||| ,
and  ||| S:520 E:524 ||| CC
imaged  ||| S:524 E:531 ||| NN
between  ||| S:531 E:539 ||| IN
January  ||| S:539 E:547 ||| NNP
2011  ||| S:547 E:552 ||| CD
and  ||| S:552 E:556 ||| CC
December  ||| S:556 E:565 ||| NNP
2013 ||| S:565 E:569 ||| CD
.  ||| S:569 E:571 ||| .
Enhancement  ||| S:571 E:583 ||| JJ
homogeneity  ||| S:583 E:595 ||| NN
and  ||| S:595 E:599 ||| CC
tumor-to-cortex  ||| S:599 E:615 ||| JJ
intensity  ||| S:615 E:625 ||| NN
ratio  ||| S:625 E:631 ||| NN
( ||| S:631 E:632 ||| -LRB-
TOC  ||| S:632 E:636 ||| NNP
ratio ||| S:636 E:641 ||| NN
)  ||| S:641 E:643 ||| -RRB-
were  ||| S:643 E:648 ||| VBD
retrospectively  ||| S:648 E:664 ||| JJ
analyzed ||| S:664 E:672 ||| NN
.  ||| S:672 E:674 ||| .
Overall ||| S:674 E:681 ||| RB
,  ||| S:681 E:683 ||| ,
heterogeneous  ||| S:683 E:697 ||| JJ
enhancement  ||| S:697 E:709 ||| NN
was  ||| S:709 E:713 ||| VBD
more  ||| S:713 E:718 ||| RBR
common  ||| S:718 E:725 ||| JJ
in  ||| S:725 E:728 ||| IN
ccRCCs  ||| S:728 E:735 ||| JJ
than  ||| S:735 E:740 ||| IN
AMLs ||| S:740 E:744 ||| NNP
,  ||| S:744 E:746 ||| ,
pRCCs ||| S:746 E:751 ||| NNP
,  ||| S:751 E:753 ||| ,
and  ||| S:753 E:757 ||| CC
cRCCs ||| S:757 E:762 ||| JJ
.  ||| S:762 E:764 ||| .
TOC  ||| S:764 E:768 ||| NNP
ratio  ||| S:768 E:774 ||| NN
showed  ||| S:774 E:781 ||| VBD
the  ||| S:781 E:785 ||| DT
trend  ||| S:785 E:791 ||| NN
ccRCC  ||| S:791 E:797 ||| NNP
>  ||| S:797 E:799 ||| NNP
AML  ||| S:799 E:803 ||| NNP
>  ||| S:803 E:805 ||| NNP
pRCC  ||| S:805 E:810 ||| NNP
=  ||| S:810 E:812 ||| SYM
cRCC ||| S:812 E:816 ||| JJ
.  ||| S:816 E:818 ||| .
Similar  ||| S:818 E:826 ||| JJ
trends  ||| S:826 E:833 ||| NNS
were  ||| S:833 E:838 ||| VBD
seen  ||| S:838 E:843 ||| VBN
in  ||| S:843 E:846 ||| IN
tumors  ||| S:846 E:853 ||| CD
< ||| S:853 E:854 ||| SYM
4  ||| S:854 E:856 ||| CD
cm ||| S:856 E:858 ||| NNS
.  ||| S:858 E:860 ||| .
Using  ||| S:860 E:866 ||| VBG
heterogeneous  ||| S:866 E:880 ||| JJ
enhancement  ||| S:880 E:892 ||| NN
or  ||| S:892 E:895 ||| CC
TOC  ||| S:895 E:899 ||| NNP
ratio  ||| S:899 E:905 ||| NN
> ||| S:905 E:906 ||| CD
107.5 ||| S:906 E:911 ||| CD
%  ||| S:911 E:913 ||| NN
to  ||| S:913 E:916 ||| TO
differentiate  ||| S:916 E:930 ||| VB
ccRCC  ||| S:930 E:936 ||| JJ
from  ||| S:936 E:941 ||| IN
other  ||| S:941 E:947 ||| JJ
histotypes ||| S:947 E:957 ||| NN
,  ||| S:957 E:959 ||| ,
the  ||| S:959 E:963 ||| DT
sensitivity ||| S:963 E:974 ||| NN
,  ||| S:974 E:976 ||| ,
specificity ||| S:976 E:987 ||| NN
,  ||| S:987 E:989 ||| ,
positive  ||| S:989 E:998 ||| JJ
and  ||| S:998 E:1002 ||| CC
negative  ||| S:1002 E:1011 ||| JJ
predictive  ||| S:1011 E:1022 ||| JJ
values  ||| S:1022 E:1029 ||| NNS
were  ||| S:1029 E:1034 ||| VBD
93.1 ||| S:1034 E:1038 ||| CD
% ||| S:1038 E:1039 ||| NN
,  ||| S:1039 E:1041 ||| ,
74.5 ||| S:1041 E:1045 ||| CD
% ||| S:1045 E:1046 ||| NN
,  ||| S:1046 E:1048 ||| ,
84.8 ||| S:1048 E:1052 ||| CD
% ||| S:1052 E:1053 ||| NN
,  ||| S:1053 E:1055 ||| ,
and  ||| S:1055 E:1059 ||| CC
87.5 ||| S:1059 E:1063 ||| CD
% ||| S:1063 E:1064 ||| NN
,  ||| S:1064 E:1066 ||| ,
respectively ||| S:1066 E:1078 ||| RB
.  ||| S:1078 E:1080 ||| .
Tumors  ||| S:1080 E:1087 ||| NNP
> ||| S:1087 E:1088 ||| CD
4  ||| S:1088 E:1090 ||| CD
cm  ||| S:1090 E:1093 ||| NNS
exhibited  ||| S:1093 E:1103 ||| VBP
considerable  ||| S:1103 E:1116 ||| JJ
overlap  ||| S:1116 E:1124 ||| NN
in  ||| S:1124 E:1127 ||| IN
enhancement  ||| S:1127 E:1139 ||| JJ
homogeneity  ||| S:1139 E:1151 ||| NN
among  ||| S:1151 E:1157 ||| IN
different  ||| S:1157 E:1167 ||| JJ
histotypes ||| S:1167 E:1177 ||| NN
.  ||| S:1177 E:1179 ||| .
TOC  ||| S:1179 E:1183 ||| NNP
ratios  ||| S:1183 E:1190 ||| NNS
were  ||| S:1190 E:1195 ||| VBD
similar  ||| S:1195 E:1203 ||| JJ
between  ||| S:1203 E:1211 ||| IN
homo-  ||| S:1211 E:1217 ||| JJ
and  ||| S:1217 E:1221 ||| CC
heterogeneously  ||| S:1221 E:1237 ||| JJ
enhancing  ||| S:1237 E:1247 ||| JJ
tumors  ||| S:1247 E:1254 ||| NNS
for  ||| S:1254 E:1258 ||| IN
ccRCCs  ||| S:1258 E:1265 ||| JJ
and  ||| S:1265 E:1269 ||| CC
for  ||| S:1269 E:1273 ||| IN
pRCCs  ||| S:1273 E:1279 ||| JJ
and  ||| S:1279 E:1283 ||| CC
cRCCs ||| S:1283 E:1288 ||| JJ
,  ||| S:1288 E:1290 ||| ,
but  ||| S:1290 E:1294 ||| CC
higher  ||| S:1294 E:1301 ||| JJR
in  ||| S:1301 E:1304 ||| IN
homogeneously  ||| S:1304 E:1318 ||| JJ
enhancing  ||| S:1318 E:1328 ||| NN
than  ||| S:1328 E:1333 ||| IN
heterogeneously  ||| S:1333 E:1349 ||| JJ
enhancing  ||| S:1349 E:1359 ||| JJ
AMLs ||| S:1359 E:1363 ||| NN
.  ||| S:1363 E:1365 ||| .
In  ||| S:1365 E:1368 ||| IN
homo-  ||| S:1368 E:1374 ||| JJ
and  ||| S:1374 E:1378 ||| CC
heterogeneously  ||| S:1378 E:1394 ||| JJ
enhancing  ||| S:1394 E:1404 ||| JJ
tumors ||| S:1404 E:1410 ||| NNS
,  ||| S:1410 E:1412 ||| ,
TOC  ||| S:1412 E:1416 ||| NNP
ratios  ||| S:1416 E:1423 ||| NNS
followed  ||| S:1423 E:1432 ||| VBD
the  ||| S:1432 E:1436 ||| DT
trends  ||| S:1436 E:1443 ||| NNS
ccRCCs  ||| S:1443 E:1450 ||| JJ
>  ||| S:1450 E:1452 ||| NNP
AMLs  ||| S:1452 E:1457 ||| NNP
>  ||| S:1457 E:1459 ||| NNP
pRCCs  ||| S:1459 E:1465 ||| NNP
=  ||| S:1465 E:1467 ||| SYM
cRCCs  ||| S:1467 E:1473 ||| JJ
and  ||| S:1473 E:1477 ||| CC
ccRCCs  ||| S:1477 E:1484 ||| NNP
>  ||| S:1484 E:1486 ||| NNP
AMLs  ||| S:1486 E:1491 ||| NNP
=  ||| S:1491 E:1493 ||| SYM
pRCCs  ||| S:1493 E:1499 ||| :
=  ||| S:1499 E:1501 ||| SYM
cRCCs ||| S:1501 E:1506 ||| JJ
,  ||| S:1506 E:1508 ||| ,
respectively ||| S:1508 E:1520 ||| RB
.  ||| S:1520 E:1522 ||| .
With  ||| S:1522 E:1527 ||| IN
TOC  ||| S:1527 E:1531 ||| NNP
ratio  ||| S:1531 E:1537 ||| NN
> ||| S:1537 E:1538 ||| CD
105.81 ||| S:1538 E:1544 ||| CD
%  ||| S:1544 E:1546 ||| NN
and  ||| S:1546 E:1550 ||| CC
> ||| S:1550 E:1551 ||| CD
72.37 ||| S:1551 E:1556 ||| CD
%  ||| S:1556 E:1558 ||| NN
to  ||| S:1558 E:1561 ||| TO
differentiate  ||| S:1561 E:1575 ||| VB
homo-  ||| S:1575 E:1581 ||| JJ
and  ||| S:1581 E:1585 ||| CC
heterogeneously  ||| S:1585 E:1601 ||| JJ
enhancing  ||| S:1601 E:1611 ||| JJ
ccRCCs  ||| S:1611 E:1618 ||| NN
from  ||| S:1618 E:1623 ||| IN
other  ||| S:1623 E:1629 ||| JJ
histotypes  ||| S:1629 E:1640 ||| NN
in  ||| S:1640 E:1643 ||| IN
tumors  ||| S:1643 E:1650 ||| CD
> ||| S:1650 E:1651 ||| CD
4  ||| S:1651 E:1653 ||| CD
cm  ||| S:1653 E:1656 ||| NN
with  ||| S:1656 E:1661 ||| IN
same  ||| S:1661 E:1666 ||| JJ
enhancement  ||| S:1666 E:1678 ||| NN
homogeneity ||| S:1678 E:1689 ||| NN
,  ||| S:1689 E:1691 ||| ,
the  ||| S:1691 E:1695 ||| DT
sensitivity ||| S:1695 E:1706 ||| NN
,  ||| S:1706 E:1708 ||| ,
specificity ||| S:1708 E:1719 ||| NN
,  ||| S:1719 E:1721 ||| ,
positive  ||| S:1721 E:1730 ||| JJ
and  ||| S:1730 E:1734 ||| CC
negative  ||| S:1734 E:1743 ||| JJ
predictive  ||| S:1743 E:1754 ||| JJ
values  ||| S:1754 E:1761 ||| NNS
were  ||| S:1761 E:1766 ||| VBD
70.0 ||| S:1766 E:1770 ||| CD
% ||| S:1770 E:1771 ||| NN
,  ||| S:1771 E:1773 ||| ,
85.7 ||| S:1773 E:1777 ||| CD
% ||| S:1777 E:1778 ||| NN
,  ||| S:1778 E:1780 ||| ,
70.0 ||| S:1780 E:1784 ||| CD
% ||| S:1784 E:1785 ||| NN
,  ||| S:1785 E:1787 ||| ,
85.7 ||| S:1787 E:1791 ||| CD
% ||| S:1791 E:1792 ||| NN
,  ||| S:1792 E:1794 ||| ,
and  ||| S:1794 E:1798 ||| CC
91.7 ||| S:1798 E:1802 ||| CD
% ||| S:1802 E:1803 ||| NN
,  ||| S:1803 E:1805 ||| ,
94.4 ||| S:1805 E:1809 ||| CD
% ||| S:1809 E:1810 ||| NN
,  ||| S:1810 E:1812 ||| ,
95.7 ||| S:1812 E:1816 ||| CD
% ||| S:1816 E:1817 ||| NN
,  ||| S:1817 E:1819 ||| ,
89.5 ||| S:1819 E:1823 ||| CD
% ||| S:1823 E:1824 ||| NN
,  ||| S:1824 E:1826 ||| ,
respectively ||| S:1826 E:1838 ||| RB
.  ||| S:1838 E:1840 ||| .
CEUS  ||| S:1840 E:1845 ||| NNP
homogeneity  ||| S:1845 E:1857 ||| NN
and  ||| S:1857 E:1861 ||| CC
TOC  ||| S:1861 E:1865 ||| NNP
ratio  ||| S:1865 E:1871 ||| NN
are  ||| S:1871 E:1875 ||| VBP
helpful  ||| S:1875 E:1883 ||| JJ
in  ||| S:1883 E:1886 ||| IN
differential  ||| S:1886 E:1899 ||| JJ
diagnosis  ||| S:1899 E:1909 ||| NN
of  ||| S:1909 E:1912 ||| IN
hypo-echoic  ||| S:1912 E:1924 ||| JJ
renal  ||| S:1924 E:1930 ||| JJ
tumor  ||| S:1930 E:1936 ||| NN
histotypes ||| S:1936 E:1946 ||| NN
.  ||| S:1946 E:1948 ||| .
Diameter  ||| S:1948 E:1957 ||| NNP
and  ||| S:1957 E:1961 ||| CC
enhancement  ||| S:1961 E:1973 ||| JJ
homogeneity  ||| S:1973 E:1985 ||| NN
should  ||| S:1985 E:1992 ||| MD
be  ||| S:1992 E:1995 ||| VB
considered  ||| S:1995 E:2006 ||| VBN
when  ||| S:2006 E:2011 ||| WRB
deciding  ||| S:2011 E:2020 ||| VBG
the  ||| S:2020 E:2024 ||| DT
diagnostic  ||| S:2024 E:2035 ||| JJ
TOC  ||| S:2035 E:2039 ||| NNP
ratio  ||| S:2039 E:2045 ||| NN
cutoff ||| S:2045 E:2051 ||| NN
.  ||| S:2051 E:2053 ||| .
